- Home
- IDR vs VYGR Comparison
IDR vs VYGR Comparison
Compare IDR & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDR
- VYGR
- Stock Information
- Founded
- IDR 1996
- VYGR 2013
- Country
- IDR United States
- VYGR United States
- Employees
- IDR N/A
- VYGR N/A
- Industry
- IDR Precious Metals
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- IDR Basic Materials
- VYGR Health Care
- Exchange
- IDR Nasdaq
- VYGR Nasdaq
- Market Cap
- IDR 154.1M
- VYGR 156.0M
- IPO Year
- IDR N/A
- VYGR 2015
- Fundamental
- Price
- IDR $12.80
- VYGR $3.12
- Analyst Decision
- IDR Strong Buy
- VYGR Strong Buy
- Analyst Count
- IDR 1
- VYGR 8
- Target Price
- IDR $17.50
- VYGR $14.33
- AVG Volume (30 Days)
- IDR 374.5K
- VYGR 969.5K
- Earning Date
- IDR 07-29-2025
- VYGR 08-05-2025
- Dividend Yield
- IDR N/A
- VYGR N/A
- EPS Growth
- IDR 144.40
- VYGR N/A
- EPS
- IDR 0.62
- VYGR N/A
- Revenue
- IDR $27,144,971.00
- VYGR $66,958,000.00
- Revenue This Year
- IDR $9.76
- VYGR N/A
- Revenue Next Year
- IDR N/A
- VYGR $78.88
- P/E Ratio
- IDR $20.62
- VYGR N/A
- Revenue Growth
- IDR 67.42
- VYGR N/A
- 52 Week Low
- IDR $9.55
- VYGR $2.65
- 52 Week High
- IDR $19.75
- VYGR $9.55
- Technical
- Relative Strength Index (RSI)
- IDR 41.19
- VYGR 46.21
- Support Level
- IDR $12.40
- VYGR $2.83
- Resistance Level
- IDR $14.29
- VYGR $3.17
- Average True Range (ATR)
- IDR 0.59
- VYGR 0.19
- MACD
- IDR -0.09
- VYGR -0.01
- Stochastic Oscillator
- IDR 16.74
- VYGR 26.88
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.